Search results for: Health Care Systems
Filter search results
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
…Institute for Health Economics (IHE) in Sweden shows that health systems and societies in general (consumers) were able to appropriate most of the life-cycle value (surplus) generated by SGAs in…
Health Expenditure in the UK
1 May 1986
Share this: Download publication Robert Chew In the UK in 1984 the combined expenditure on health care services by both the public and private sectors rose to a record total…
Pharmaceuticals in seven nations
1 May 1985
…becoming increasingly important to the economic prosperity of the advanced nations of the world.1 These industries need political understanding if they are to make their full contribution to the health…
Overview of the Economics of the Market for Medicines in the UK
29 March 2012
…His presentation covers the key issues, from drug development through health technology assessment and market access. Economics of the Market for Medicines in the UK from Office of Health Economics…
The Tougher the Better: The Effect of GP Performance Thresholds in Scotland
20 April 2012
…that the QOF achievement has had a negligible impact on health outcomes. The OHE’s Yan Feng and her colleagues take a closer look at the effect of changes in the…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 May 2012
…affect their health in future. Current pricing and reimbursement systems for diagnostics, however, are not efficient and provide poor incentives for new diagnostic approaches. Prices often are driven by administrative…
OHE Models Future UK Medicines Spending for the ABPI
3 July 2012
The Office of Health Economics has developed and run a model for the ABPI to project UK NHS expenditure on medicines. On 2 July, the ABPI released its projections for…
OHE Conference on the Future of Drug Development – Register Now
5 September 2012
…of UK and EU regulatory agencies, the pharmaceutical industry and payers — as well as leading experts in health technology assessment, pricing and reimbursement, and R&D structure and incentives. Among…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…the long-term investments involved. The Office of Health Economics today released a comprehensive study of the cost of R&D for new medicines. How much it costs to research and develop…